The District filed a complaint in D.C. Superior Court alleging GSK broke laws in the way it promoted the drugs, according to a statement from D.C. Attorney General Irvin B. Nathan.

The complaint accused GSK of promoting Advair for treatment of mild and intermittent asthma, even though the federal Food and Drug Administration only approved it for treatment of more serious asthma conditions.

The company also allegedly promoted Wellbutrin for treatment of weight loss and sexual dysfunction through its "happy, horny, skinny pill" campaign, even though these were unapproved uses, the complaint shows.

As part of the settlement, the drug company will be required to continue a program which ends the practice of basing salespeople's compensation on their sales volumes and bar them from making promotional claims that their products are better, safer, more effective or have fewer side effects than have been demonstrated in clinical studies.

GSK must also provide samples of their products only to health care professionals who are expected to prescribe them for approved uses and not provide information recommending off-label use, unless allowed by the U.S. Food and Drug Administration, officials announced.